Insider · CIK 0001704132
Foresite Capital Management IV, LLC
Files at EIKN (Eikon Therapeutics, Inc.). First filing Feb 6, 2026, latest Feb 6, 2026.
In brief
Foresite Capital Management IV, LLC files SEC Form 4 as 10% owner at EIKN (Eikon Therapeutics, Inc.). Since Feb 6, 2026, Foresite Capital Management IV, LLC has reported 1 open-market buy worth $1000k and 0 open-market sells worth $0, the latest filed on Feb 6, 2026.
A track record needs three past buys with six months of prices behind them; Foresite Capital Management IV, LLC has 0, so none is measured yet.
The newest scored trade: bought $1000k of EIKN on Feb 4, 2026, filed Feb 6, 2026, scored 47 (moderate). In the last 12 months: 1 buy worth $1000k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EIKN: Eikon Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | Eikon Therapeutics, Inc. | $1000k 55,555 shares | +4% | - |
Transactions
Every row this insider has filed, 29 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +1,340,878 | $0.00 | $0 | 1,340,878 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +335,521 | $0.00 | $0 | 1,676,399 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +37,855 | $0.00 | $0 | 1,714,254 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +229,428 | $0.00 | $0 | 1,943,682 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +697,885 | $0.00 | $0 | 697,885 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +37,855 | $0.00 | $0 | 735,740 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +1,626 | $0.00 | $0 | 737,366 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +67,207 | $0.00 | $0 | 804,573 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +458,855 | $0.00 | $0 | 1,263,428 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +348,942 | $0.00 | $0 | 348,942 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +37,855 | $0.00 | $0 | 386,797 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +922 | $0.00 | $0 | 387,719 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +38,133 | $0.00 | $0 | 425,852 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Common Stockindirect: See Footnote | +408,725 | $0.00 | $0 | 408,725 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +55,555 | $18.00 | $1000k | 1,318,983 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A Preferred Stockderivativeindirect: See Footnote | -10,000,000 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: See Footnote | -2,502,252 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: See Footnote | -5,204,684 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series A-1 Preferred Stockderivativeindirect: See Footnote | -2,602,342 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -282,317 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -282,317 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -282,317 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -3,048,192 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C Preferred Stockderivativeindirect: See Footnote | -12,123 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C Preferred Stockderivativeindirect: See Footnote | -6,878 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See Footnote | -501,219 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See Footnote | -284,392 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series D Preferred Stockderivativeindirect: See Footnote | -1,711,025 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | EIKN Eikon Therapeutics, Inc. | CConversion Series D Preferred Stockderivativeindirect: See Footnote | -3,422,051 | $0.00 | $0 | 0 | Feb 6, 2026 |
Questions about Foresite Capital Management IV, LLC
Answered from the filings on this page, as of the latest one.
Is Foresite Capital Management IV, LLC buying or selling?
In the last 12 months Foresite Capital Management IV, LLC reported 1 open-market buy worth $1000k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $1000k of EIKN on Feb 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Foresite Capital Management IV, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Foresite Capital Management IV, LLC has 0.
Where does Foresite Capital Management IV, LLC file Form 4?
Foresite Capital Management IV, LLC has filed Form 4 at EIKN (Eikon Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.